Use of estriol for treatment of climacteric osteoporosis

US5614213A · kind A · utility

Assignee

• EnTec Gesellschaft fuer Endokrinologische Technologie m.b.H. · DE

Inventors

• Walter Elger · Berlin, DE
• Birgitt Schneider · Jena, DE
• Michael Oettel · Jena, DE
• Michael ERNST · Jena, DE
• Doris Hubler · Jena, DE
• Michael Dittgen · Apolda, DE

Key dates

• Filing date: Aug 31, 1994
• Grant date: Mar 25, 1997
• Expiry date: Aug 31, 2014

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has up until now been thought ineffective for the treatment of climacteric osteoporosis, develops strong anti-osteoporotic effectiveness upon continuous transdermal application.